PubMed:32074786 / 1450-1664 JSONTXT

{"project":"LitCovid-PAS-Enju","denotations":[{"id":"EnjuParser_T224","span":{"begin":0,"end":11},"obj":"JJ"},{"id":"EnjuParser_T225","span":{"begin":12,"end":19},"obj":"NN"},{"id":"EnjuParser_T226","span":{"begin":20,"end":22},"obj":"VBZ"},{"id":"EnjuParser_T227","span":{"begin":23,"end":29},"obj":"RB"},{"id":"EnjuParser_T228","span":{"begin":30,"end":41},"obj":"VBN"},{"id":"EnjuParser_T229","span":{"begin":42,"end":45},"obj":"IN"},{"id":"EnjuParser_T230","span":{"begin":46,"end":62},"obj":"JJ"},{"id":"EnjuParser_T231","span":{"begin":63,"end":69},"obj":"NN"},{"id":"EnjuParser_T232","span":{"begin":70,"end":72},"obj":"IN"},{"id":"EnjuParser_T233","span":{"begin":73,"end":81},"obj":"VBN"},{"id":"EnjuParser_T234","span":{"begin":82,"end":88},"obj":"NNS"},{"id":"EnjuParser_T235","span":{"begin":89,"end":93},"obj":"WDT"},{"id":"EnjuParser_T236","span":{"begin":94,"end":98},"obj":"VBP"},{"id":"EnjuParser_T237","span":{"begin":99,"end":102},"obj":"DT"},{"id":"EnjuParser_T238","span":{"begin":103,"end":114},"obj":"NNS"},{"id":"EnjuParser_T239","span":{"begin":115,"end":117},"obj":"IN"},{"id":"EnjuParser_T240","span":{"begin":118,"end":122},"obj":"NN"},{"id":"EnjuParser_T241","span":{"begin":123,"end":132},"obj":"NN"},{"id":"EnjuParser_T242","span":{"begin":133,"end":134},"obj":"-LRB-"},{"id":"EnjuParser_T243","span":{"begin":134,"end":141},"obj":"JJ"},{"id":"EnjuParser_T244","span":{"begin":142,"end":148},"obj":"NN"},{"id":"EnjuParser_T245","span":{"begin":149,"end":150},"obj":"NN"},{"id":"EnjuParser_T246","span":{"begin":151,"end":156},"obj":"NN"},{"id":"EnjuParser_T247","span":{"begin":157,"end":158},"obj":"VBP"},{"id":"EnjuParser_T248","span":{"begin":159,"end":167},"obj":"JJ"},{"id":"EnjuParser_T249","span":{"begin":168,"end":174},"obj":"NN"},{"id":"EnjuParser_T250","span":{"begin":175,"end":176},"obj":"NN"},{"id":"EnjuParser_T251","span":{"begin":177,"end":182},"obj":"NN"},{"id":"EnjuParser_T252","span":{"begin":183,"end":184},"obj":"VBP"},{"id":"EnjuParser_T253","span":{"begin":185,"end":199},"obj":"JJ"},{"id":"EnjuParser_T254","span":{"begin":200,"end":205},"obj":"NN"},{"id":"EnjuParser_T255","span":{"begin":206,"end":212},"obj":"NN"},{"id":"EnjuParser_T256","span":{"begin":212,"end":213},"obj":"-RRB-"}],"relations":[{"id":"EnjuParser_R238","pred":"arg1Of","subj":"EnjuParser_T225","obj":"EnjuParser_T224"},{"id":"EnjuParser_R239","pred":"arg1Of","subj":"EnjuParser_T225","obj":"EnjuParser_T226"},{"id":"EnjuParser_R240","pred":"arg2Of","subj":"EnjuParser_T228","obj":"EnjuParser_T226"},{"id":"EnjuParser_R241","pred":"arg1Of","subj":"EnjuParser_T228","obj":"EnjuParser_T227"},{"id":"EnjuParser_R242","pred":"arg2Of","subj":"EnjuParser_T225","obj":"EnjuParser_T228"},{"id":"EnjuParser_R243","pred":"arg1Of","subj":"EnjuParser_T228","obj":"EnjuParser_T229"},{"id":"EnjuParser_R244","pred":"arg2Of","subj":"EnjuParser_T231","obj":"EnjuParser_T229"},{"id":"EnjuParser_R245","pred":"arg1Of","subj":"EnjuParser_T231","obj":"EnjuParser_T230"},{"id":"EnjuParser_R246","pred":"arg1Of","subj":"EnjuParser_T228","obj":"EnjuParser_T232"},{"id":"EnjuParser_R247","pred":"arg2Of","subj":"EnjuParser_T234","obj":"EnjuParser_T232"},{"id":"EnjuParser_R248","pred":"arg2Of","subj":"EnjuParser_T234","obj":"EnjuParser_T233"},{"id":"EnjuParser_R249","pred":"arg1Of","subj":"EnjuParser_T234","obj":"EnjuParser_T235"},{"id":"EnjuParser_R250","pred":"arg1Of","subj":"EnjuParser_T234","obj":"EnjuParser_T236"},{"id":"EnjuParser_R251","pred":"arg2Of","subj":"EnjuParser_T238","obj":"EnjuParser_T236"},{"id":"EnjuParser_R252","pred":"arg1Of","subj":"EnjuParser_T238","obj":"EnjuParser_T237"},{"id":"EnjuParser_R253","pred":"arg1Of","subj":"EnjuParser_T238","obj":"EnjuParser_T239"},{"id":"EnjuParser_R254","pred":"arg2Of","subj":"EnjuParser_T241","obj":"EnjuParser_T239"},{"id":"EnjuParser_R255","pred":"arg1Of","subj":"EnjuParser_T241","obj":"EnjuParser_T240"},{"id":"EnjuParser_R256","pred":"arg1Of","subj":"EnjuParser_T238","obj":"EnjuParser_T242"},{"id":"EnjuParser_R257","pred":"arg2Of","subj":"EnjuParser_T247","obj":"EnjuParser_T242"},{"id":"EnjuParser_R258","pred":"arg3Of","subj":"EnjuParser_T256","obj":"EnjuParser_T242"},{"id":"EnjuParser_R259","pred":"arg1Of","subj":"EnjuParser_T246","obj":"EnjuParser_T243"},{"id":"EnjuParser_R260","pred":"arg1Of","subj":"EnjuParser_T246","obj":"EnjuParser_T244"},{"id":"EnjuParser_R261","pred":"arg1Of","subj":"EnjuParser_T246","obj":"EnjuParser_T245"},{"id":"EnjuParser_R262","pred":"arg1Of","subj":"EnjuParser_T246","obj":"EnjuParser_T247"},{"id":"EnjuParser_R263","pred":"arg2Of","subj":"EnjuParser_T251","obj":"EnjuParser_T247"},{"id":"EnjuParser_R264","pred":"arg3Of","subj":"EnjuParser_T252","obj":"EnjuParser_T247"},{"id":"EnjuParser_R265","pred":"arg1Of","subj":"EnjuParser_T251","obj":"EnjuParser_T248"},{"id":"EnjuParser_R266","pred":"arg1Of","subj":"EnjuParser_T251","obj":"EnjuParser_T249"},{"id":"EnjuParser_R267","pred":"arg1Of","subj":"EnjuParser_T251","obj":"EnjuParser_T250"},{"id":"EnjuParser_R268","pred":"arg1Of","subj":"EnjuParser_T251","obj":"EnjuParser_T252"},{"id":"EnjuParser_R269","pred":"arg2Of","subj":"EnjuParser_T255","obj":"EnjuParser_T252"},{"id":"EnjuParser_R270","pred":"arg1Of","subj":"EnjuParser_T255","obj":"EnjuParser_T253"},{"id":"EnjuParser_R271","pred":"arg1Of","subj":"EnjuParser_T255","obj":"EnjuParser_T254"}],"text":"Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage ≥ 2/rectal cancer T stage ≥ 3/unresectable colon cancer)."}

{"project":"LitCovid-ArguminSci","denotations":[{"id":"T11","span":{"begin":0,"end":156},"obj":"DRI_Background"},{"id":"T12","span":{"begin":168,"end":182},"obj":"DRI_Background"},{"id":"T13","span":{"begin":200,"end":214},"obj":"DRI_Background"}],"text":"Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage ≥ 2/rectal cancer T stage ≥ 3/unresectable colon cancer)."}

{"project":"LitCovid-OGER","denotations":[{"id":"T2","span":{"begin":200,"end":205},"obj":"UBERON:0001155"}],"namespaces":[{"prefix":"PR","uri":"http://purl.obolibrary.org/obo/PR_"},{"prefix":"UBERON","uri":"http://purl.obolibrary.org/obo/UBERON_"}],"text":"Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage ≥ 2/rectal cancer T stage ≥ 3/unresectable colon cancer)."}

{"project":"LitCovid-PubTatorCentral","denotations":[{"id":"T14","span":{"begin":46,"end":69},"obj":"Disease:MESH:D005770"},{"id":"T15","span":{"begin":134,"end":150},"obj":"Disease:MESH:D013274"},{"id":"T16","span":{"begin":161,"end":176},"obj":"Disease:MESH:D012004"},{"id":"T17","span":{"begin":200,"end":212},"obj":"Disease:MESH:D015179"}],"text":"Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage ≥ 2/rectal cancer T stage ≥ 3/unresectable colon cancer)."}

{"project":"LitCovid-OGER-BB","denotations":[{"id":"T8","span":{"begin":46,"end":62},"obj":"UBERON:0005409"},{"id":"T9","span":{"begin":134,"end":141},"obj":"UBERON:0005409"},{"id":"T10","span":{"begin":161,"end":167},"obj":"UBERON:0001052"},{"id":"T11","span":{"begin":200,"end":205},"obj":"UBERON:0001155"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage ≥ 2/rectal cancer T stage ≥ 3/unresectable colon cancer)."}

{"project":"LitCovid-sentences-v1","denotations":[{"id":"TextSentencer_T11","span":{"begin":0,"end":214},"obj":"Sentence"}],"text":"Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage ≥ 2/rectal cancer T stage ≥ 3/unresectable colon cancer)."}

{"project":"LitCovid-TimeML","denotations":[{"id":"tok240","span":{"begin":0,"end":11},"obj":"NNP"},{"id":"tok241","span":{"begin":12,"end":19},"obj":"NN"},{"id":"tok242","span":{"begin":20,"end":22},"obj":"VBZ"},{"id":"tok243","span":{"begin":23,"end":29},"obj":"RB"},{"id":"tok244","span":{"begin":30,"end":41},"obj":"VBN"},{"id":"tok245","span":{"begin":42,"end":45},"obj":"IN"},{"id":"tok246","span":{"begin":46,"end":62},"obj":"NN"},{"id":"tok247","span":{"begin":63,"end":69},"obj":"NN"},{"id":"tok248","span":{"begin":70,"end":72},"obj":"IN"},{"id":"tok249","span":{"begin":73,"end":81},"obj":"VBD"},{"id":"tok250","span":{"begin":82,"end":88},"obj":"NNS"},{"id":"tok251","span":{"begin":89,"end":93},"obj":"WDT"},{"id":"tok252","span":{"begin":94,"end":98},"obj":"VBP"},{"id":"tok253","span":{"begin":99,"end":102},"obj":"DT"},{"id":"tok254","span":{"begin":103,"end":114},"obj":"NNS"},{"id":"tok255","span":{"begin":115,"end":117},"obj":"IN"},{"id":"tok256","span":{"begin":118,"end":122},"obj":"NNP"},{"id":"tok257","span":{"begin":123,"end":132},"obj":"NN"},{"id":"tok258","span":{"begin":133,"end":134},"obj":"("},{"id":"tok259","span":{"begin":134,"end":141},"obj":"JJ"},{"id":"tok260","span":{"begin":142,"end":148},"obj":"NN"},{"id":"tok261","span":{"begin":149,"end":150},"obj":"NN"},{"id":"tok262","span":{"begin":151,"end":156},"obj":"NN"},{"id":"tok263","span":{"begin":157,"end":158},"obj":"NN"},{"id":"tok264","span":{"begin":159,"end":160},"obj":"CD"},{"id":"tok265","span":{"begin":160,"end":161},"obj":"NN"},{"id":"tok266","span":{"begin":161,"end":167},"obj":"NN"},{"id":"tok267","span":{"begin":168,"end":174},"obj":"NN"},{"id":"tok268","span":{"begin":175,"end":176},"obj":"NN"},{"id":"tok269","span":{"begin":177,"end":182},"obj":"NN"},{"id":"tok270","span":{"begin":183,"end":184},"obj":"NN"},{"id":"tok271","span":{"begin":185,"end":186},"obj":"CD"},{"id":"tok272","span":{"begin":186,"end":187},"obj":"NN"},{"id":"tok273","span":{"begin":187,"end":199},"obj":"JJ"},{"id":"tok274","span":{"begin":200,"end":205},"obj":"NN"},{"id":"tok275","span":{"begin":206,"end":212},"obj":"NN"},{"id":"tok276","span":{"begin":212,"end":213},"obj":")"},{"id":"tok277","span":{"begin":213,"end":214},"obj":"."},{"id":"lookup38","span":{"begin":20,"end":22},"obj":"country_code"},{"id":"lookup39","span":{"begin":70,"end":72},"obj":"country_code"},{"id":"lookup40","span":{"begin":200,"end":205},"obj":"currency_unit"},{"id":"lookup41","span":{"begin":200,"end":205},"obj":"person_first"},{"id":"event16","span":{"begin":30,"end":41},"obj":"I_ACTION"},{"id":"event22","span":{"begin":73,"end":81},"obj":"OCCURRENCE"},{"id":"event35","span":{"begin":94,"end":98},"obj":"OCCURRENCE"}],"text":"Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage ≥ 2/rectal cancer T stage ≥ 3/unresectable colon cancer)."}

{"project":"LitCovid-PD-MONDO-v1","denotations":[{"id":"T16","span":{"begin":63,"end":69},"obj":"Disease"},{"id":"T17","span":{"begin":134,"end":148},"obj":"Disease"},{"id":"T18","span":{"begin":142,"end":148},"obj":"Disease"},{"id":"T19","span":{"begin":161,"end":174},"obj":"Disease"},{"id":"T21","span":{"begin":168,"end":174},"obj":"Disease"},{"id":"T22","span":{"begin":200,"end":212},"obj":"Disease"},{"id":"T23","span":{"begin":206,"end":212},"obj":"Disease"}],"attributes":[{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0001056"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0006519"},{"id":"A20","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0044937"},{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0021063"},{"id":"A23","pred":"mondo_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage ≥ 2/rectal cancer T stage ≥ 3/unresectable colon cancer)."}

{"project":"LitCovid-PD-HP-v1","denotations":[{"id":"T8","span":{"begin":63,"end":69},"obj":"Phenotype"},{"id":"T9","span":{"begin":134,"end":148},"obj":"Phenotype"},{"id":"T10","span":{"begin":168,"end":174},"obj":"Phenotype"},{"id":"T11","span":{"begin":200,"end":212},"obj":"Phenotype"}],"attributes":[{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0012126"},{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0003003"}],"text":"Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage ≥ 2/rectal cancer T stage ≥ 3/unresectable colon cancer)."}

{"project":"LitCovid-PD-FMA-UBERON-v1","denotations":[{"id":"T2","span":{"begin":200,"end":205},"obj":"Body_part"}],"attributes":[{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma14543"},{"id":"A67742","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0001155"}],"text":"Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage ≥ 2/rectal cancer T stage ≥ 3/unresectable colon cancer)."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T2","span":{"begin":200,"end":205},"obj":"Body_part"}],"attributes":[{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma14543"}],"text":"Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage ≥ 2/rectal cancer T stage ≥ 3/unresectable colon cancer)."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T2","span":{"begin":200,"end":205},"obj":"Body_part"}],"attributes":[{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0001155"}],"text":"Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage ≥ 2/rectal cancer T stage ≥ 3/unresectable colon cancer)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T16","span":{"begin":63,"end":69},"obj":"Disease"},{"id":"T17","span":{"begin":134,"end":148},"obj":"Disease"},{"id":"T18","span":{"begin":142,"end":148},"obj":"Disease"},{"id":"T19","span":{"begin":161,"end":174},"obj":"Disease"},{"id":"T21","span":{"begin":168,"end":174},"obj":"Disease"},{"id":"T22","span":{"begin":200,"end":212},"obj":"Disease"},{"id":"T23","span":{"begin":206,"end":212},"obj":"Disease"}],"attributes":[{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0001056"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0006519"},{"id":"A20","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0044937"},{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0021063"},{"id":"A23","pred":"mondo_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"}],"text":"Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage ≥ 2/rectal cancer T stage ≥ 3/unresectable colon cancer)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T7","span":{"begin":200,"end":205},"obj":"http://purl.obolibrary.org/obo/UBERON_0001155"}],"text":"Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage ≥ 2/rectal cancer T stage ≥ 3/unresectable colon cancer)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":118,"end":122},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_29308"}],"text":"Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage ≥ 2/rectal cancer T stage ≥ 3/unresectable colon cancer)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T8","span":{"begin":63,"end":69},"obj":"Phenotype"},{"id":"T9","span":{"begin":134,"end":148},"obj":"Phenotype"},{"id":"T10","span":{"begin":168,"end":174},"obj":"Phenotype"},{"id":"T11","span":{"begin":200,"end":212},"obj":"Phenotype"}],"attributes":[{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0012126"},{"id":"A10","pred":"hp_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/HP_0002664"},{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0003003"}],"text":"Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage ≥ 2/rectal cancer T stage ≥ 3/unresectable colon cancer)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T11","span":{"begin":0,"end":214},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage ≥ 2/rectal cancer T stage ≥ 3/unresectable colon cancer)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"52","span":{"begin":46,"end":69},"obj":"Disease"},{"id":"53","span":{"begin":134,"end":148},"obj":"Disease"},{"id":"54","span":{"begin":168,"end":174},"obj":"Disease"},{"id":"55","span":{"begin":200,"end":212},"obj":"Disease"}],"attributes":[{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"MESH:D004067"},{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"MESH:D013274"},{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"MESH:D009369"},{"id":"A55","pred":"tao:has_database_id","subj":"55","obj":"MESH:D015179"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage ≥ 2/rectal cancer T stage ≥ 3/unresectable colon cancer)."}

{"project":"Inflammaging","denotations":[{"id":"T11","span":{"begin":0,"end":214},"obj":"Sentence"},{"id":"T11","span":{"begin":0,"end":214},"obj":"Sentence"}],"text":"Neoadjuvant therapy is highly recommended for gastrointestinal cancer at advanced stages that meet the indications of NCCN guideline (gastric cancer T stage ≥ 2/rectal cancer T stage ≥ 3/unresectable colon cancer)."}